During Thursday’s trading session, the shares of an integrated research, development, and manufacturing services company slumped nearly 12 percent on BSE, despite the company reporting Q4 FY25 financial results with a revenue from operations increase of 8 percent QoQ and nearly 11 percent YoY.
Price Movement
With a market cap of Rs. 26,706.3 crores, at 11:51 a.m., the shares of Syngene International Limited were trading in the red at Rs. 663.9, down by nearly 11.5 percent, compared to its previous closing price of Rs. 750.05.
So far in 2025, the stock has delivered negative returns of around 24 percent, and has fallen by about 8 percent in the last one month.
What’s the News
The fluctuations in the share prices were observed after Syngene International Limited announced the financial results for Q4 FY25, through the latest filings with the stock exchanges on Wednesday, post-market hours.
For Q4 FY25, Syngene International reported a consolidated revenue from operations of Rs. 1,018 crores, reflecting a growth of around 8 percent QoQ from Rs. 943.7 crores in Q3 FY25, and a year-on-year rise of around 11 percent from Rs. 917 crores in Q4 FY24. Notably, this is the first time the company’s quarterly revenue from operations has crossed the Rs. 1,000 crore mark.
Net profit surged significantly to Rs. 183.3 crore in Q4 FY25, a significant 40 percent increase over the Rs. 131 crore reported in the previous quarter, but a 3 percent decline compared to Rs. 188.6 crore in Q4 FY24.
During the same period, EBITDA also improved to Rs. 344 crore, growing by 21 percent QoQ and 8.5 percent YoY, reflecting good underlying fundamentals. However, EBITDA margins stood at 34 percent in Q4 FY25, up from 30 percent in Q3 FY25, but down from 35 percent in Q4 FY24.
The company’s Board has recommended a final dividend of Re. 1.25 per Equity Share for FY25. The record date is fixed as Friday, 27th June 2025, for the payment of the dividend.
Management Comments
Peter Bains, Managing Director and CEO of the company, stated that the highlight of the quarter was the acquisition of a state-of-the-art biologics manufacturing facility in the United States. This move has strengthened Syngene’s position in the rapidly expanding biologics CDMO sector and provided a strategic entry point into the US market.
He noted that the company’s biologics CDMO business experienced strong growth, driven by commercial manufacturing and the addition of new development projects. Furthermore, the research division saw continued momentum, supported by a high conversion rate of pilot projects into full-scale programs within discovery services.
Syngene is well-positioned to expand its market share, backed by a 30-year track record of delivering innovative science, high-quality solutions, and value to its growing global customer base.
About the Company
Syngene International Limited is engaged in the business of providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide.
Syngene’s services include integrated drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development, along with clinical development services.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
